Is National HealthCare (NHC) overvalued or fairly valued?

MarketChacha shows National HealthCare's valuation in context — a trailing P/E of about 24.8, a forward P/E of about 512.2, a price-to-book of about 3.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does National HealthCare's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.40×) from reported figures — education, not a rating.

What is National HealthCare's revenue?

National HealthCare reported revenue of $1.5B for FY2025, with net profit of $120.0M, per official filings.

What is the share price of National HealthCare (NHC)?

National HealthCare last traded at $218.64 (-1.4% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

National HealthCare

NHC · NYSE · Healthcare · United States

Snapshot

TickerNHC

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees15,278

HeadquartersMurfreesboro, United States

Websitewww.nhccare.com

Filings tracked22

About National HealthCare

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. It operates through two segments: Inpatient and Homecare and Hospice Services. The company's skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. It provides medical specialty units comprise memory care units and sub-acute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, the company offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.

Who owns it

Insiders18.8%
Institutions66.9%
Public & other14.3%

353 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.62%
Morgan Stanley Institutional Investment Advisors LLC6.57%
Dimensional Fund Advisors LP5.94%
Vanguard Portfolio Management LLC5.17%
First Trust Advisors LP4.66%
Vanguard Capital Management LLC3.53%
State Street Corporation3.36%
Geode Capital Management, LLC2.43%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.40×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend5.9% → 7.9%

Margin has expanded by about 2.1 points — the business is getting more profitable.

Growth qualityrev 15% · PAT 34%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.5B

Net margin

7.9%

ROE

11.2%

Revenue CAGR (2y)

+15.3%

Profit CAGR (2y)

+34.0%

EPS (FY2025)

7.67

Net profit (FY2025)

$120.0M

Ask MarketChacha about NHC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.5B	$120.0M	7.67	7.9%	11.2%
FY2024	$1.3B	$101.9M	6.53	7.8%	10.4%
FY2023	$1.1B	$66.8M	4.34	5.9%	7.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$408.0M	$40.3M	2.54	9.9%
2026Q1	$381.8M	$35.9M	2.27	9.4%
2025Q3	$382.7M	$39.2M	2.50	10.3%
2025Q2	$374.9M	$23.7M	1.52	6.3%
2025Q1	$373.7M	$32.2M	2.07	8.6%
2024Q3	$340.2M	$42.8M	2.73	12.6%
2024Q2	$300.7M	$26.8M	1.73	8.9%
2024Q1	$297.2M	$26.2M	1.69	8.8%
2023Q3	$288.5M	$10.4M	0.68	3.6%
2023Q2	$282.6M	$16.3M	1.06	5.8%
2023Q1	$269.6M	$11.7M	0.76	4.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q — FORM 10-Q
SEC8/6/2026
8-K — Material agreement, Termination of agreement, Completion of acquisition/disposition, Material financial obligation, Reg FD disclosure, Exhibits
SEC7/1/2026material
8-K — Material agreement, Termination of agreement, Material financial obligation, Exhibits
SEC5/27/2026material
8-K — Material agreement, Exhibits
SEC5/15/2026material
8-K — Shareholder vote results
SEC5/13/2026material
8-K — Results of operations, Exhibits
SEC5/8/2026material
8-K — Other events, Exhibits
SEC5/7/2026material
10-Q — FORM 10-Q
SEC5/7/2026
8-K — Material agreement, Termination of agreement, Reg FD disclosure, Exhibits
SEC4/22/2026material
8-K — Results of operations, Exhibits
SEC2/27/2026material
10-K — FORM 10-K
SEC2/26/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC2/17/2026material
8-K — Other events, Exhibits
SEC2/13/2026material

2025

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC11/12/2025material
8-K — Results of operations, Exhibits
SEC11/7/2025material
8-K — Other events, Exhibits
SEC11/7/2025material
10-Q — FORM 10-Q
SEC11/6/2025
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/26/2025material
8-K — Other events
SEC9/12/2025material
8-K — Other events, Exhibits
SEC8/8/2025material
8-K — Results of operations, Exhibits
SEC8/8/2025material
10-Q — FORM 10-Q
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.